TARA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TARA is in a strong short-term uptrend, but it’s extended/overbought (RSI76) and trading just below near-term resistance (7.20). With no proprietary buy signals today and no fresh news catalysts, the risk/reward for an immediate entry is unfavorable versus waiting for a pullback closer to the ~6.17 pivot support.
Trend is bullish: SMA_5 > SMA_20 > SMA_200 confirms an uptrend. Momentum is still positive (MACD histogram +0.21) but is positively contracting, suggesting upside momentum is slowing. RSI_6 at ~76.5 indicates an overbought/extended condition. Key levels: Pivot support ~6.168 (better dip-buy zone), resistance R1 ~7.199 and R2 ~7.836. Current post-market ~7 is close to R1, increasing the odds of churn or pullback rather than clean immediate continuation.
Bullish technical trend (stacked moving averages). Strongly bullish options skew (heavy calls, very low put interest). Recent initiation: Piper Sandler Overweight with a high $24 target, framing multiple potential market opportunities. Pattern-based outlook suggests mild positive drift over 1 week to 1 month (+1.83% / +2.67%).
with slowing momentum (MACD contraction), making immediate entry less attractive. No news catalysts in the past week to drive follow-through. Clinical-stage biotech risk profile with minimal revenue and ongoing losses; high IV implies the market expects large swings. No notable hedge fund/insider accumulation trends recently; no congress trading data to confirm influential buying.
2025/Q3: still effectively pre-revenue (Revenue 0, flat YoY). Net loss improved to -$13.26M (18.17% better YoY), but EPS fell to -$0.31 (38% worse YoY), indicating per-share results deteriorated despite the headline loss improvement. Overall: cash-burn/clinical-stage profile remains, with no demonstrated revenue growth trend yet.
Recent analyst activity is positive but limited in breadth: on 2026-01-07 Piper Sandler initiated with Overweight and a $24 price target, highlighting “under-the-radar” status and multiple potential opportunities. Wall Street-style pros: large upside narrative if pipeline succeeds and current price is far below target. Cons: single/limited coverage signal, valuation is hard to anchor without revenue, and outcomes hinge on clinical milestones rather than fundamentals.
